Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NCCAM research centers added

This article was originally published in The Tan Sheet

Executive Summary

The National Center for Complementary and Alternative Medicine has added three new Centers of Excellence for Research on CAM, the center announces Oct. 5. The centers will "explore the biological effects of a number of plant-derived compounds and preparations found in CAM products, such as dietary supplements, on pancreatic diseases, autoimmune and inflammatory diseases, and Alzheimer's disease," NCCAM notes. The first center, the UCLA Center of Excellence in Pancreatic Diseases, will study curcumin, lycopene, green tea and scutellari baicalensis to determine the effects the plant compounds have on the prevention and/or treatment of pancreatic cancer and pancreatitis. The second center, the center for CAM research on autoimmune and inflammatory diseases, will study the mechanisms by which resveratrol may aid in the treatment of multiple sclerosis, among other things. The third center will examine polyphenols effect on Alzheimer's disease. The center grants will provide five years of support...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts